EICHOR
● Not Yet Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: AbbVie
About this study
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein will be enrolled. Approximately 180 participants will be enrolled in the study at sites worldwide. Participants will receive intravenous doses of telisotuzumab adizutecan with intravenous pembrolizumab, or standard of care (SOC) chemotherapy with pembrolizumab. Participants will receive treatment as part of a 38 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits every 3 weeks during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing …
This description comes directly from the study's public registry record.
Talk to the study team
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
Locations (20)
| University of Arkansas for Medical Sciences /ID# 283444 | Little Rock, Arkansas, United States | — |
| Winship Cancer Institute of Emory University /ID# 282003 | Atlanta, Georgia, United States | — |
| University of Chicago Medical Center /ID# 281748 | Chicago, Illinois, United States | — |
| OU Health - Stephenson Cancer Center /ID# 282905 | Oklahoma City, Oklahoma, United States | — |
| UT Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center /ID# 283638 | Dallas, Texas, United States | — |
| University of Virginia /ID# 281773 | Charlottesville, Virginia, United States | — |
| Anhui Cancer Hospital /ID# 282354 | Hefei, Anhui, China | — |
| People's Hospital of Henan Province /ID# 282036 | Zhengzhou, Henan, China | — |
| Hunan Province Cancer Hospital /ID# 282346 | Changsha, Hunan, China | — |
| The First Affiliated Hospital of Xi'an Jiaotong University /ID# 282115 | Xi'an, Shaanxi, China | — |
| Fudan University Shanghai Cancer Center /ID# 282374 | Shanghai, Shanghai Municipality, China | — |
| Aichi Cancer Center /ID# 282273 | Nagoya, Aichi-ken, Japan | — |
+ 8 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07744126